top of page

Guidance on CMC Changes to an Approved Application- US-FDA

FDA issued final guidance on June 21, 2021 to aid applicants of certain licensed biological products to determine the appropriate reporting category for a change in chemistry, manufacturing, and controls (CMC) information to an approved biologics license application (BLA).

This guidance finalizes the draft guidance, “Chemistry, Manufacturing, and Controls Changes to an Approved Application: Certain Biological Products” dated December 2017, and supersedes the guidance entitled “Guidance for Industry: Changes to an Approved Application: Biological Products” dated 1997 (July 1997 guidance).

The guidance details reporting categories such as Prior Approval Supplement (PAS), Changes Being Effected in 30 Days/Changes Being Effected Supplements (CBE30/CBE), and Annual Report.

The assessment of a change by the applicant and by the FDA is also discussed. The document also provides the requirements for submitting changes to the agency and recommendations for reporting categories.

16 views0 comments


bottom of page